Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

Benzinga

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Major Insurers Scale Back Medicare Advantage and Part D Plans for 2026

Beneficiaries enrolled in Medicare Advantage and Part D prescription drug plans might be losing their plan as UnitedHealthcare, Humana, and Aetna (CVS Health) scale back offerings for 2026.

Kiplinger

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?

Processa Pharmaceuticals Inc. (NASDAQ:PCSA) shares soared 37.5% to $0.50 during after-hours trading on Tuesday.

Benzinga

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains

A wider range of stocks have been gaining traction lately as major indexes push toward record highs. The SPDR SP Biotech ETF (NYSE:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AMD's OpenAI Deal Could Spark A New AI Arms Race With Nvidia

Advanced Micro Devices Inc.’s (NASDAQ:AMD) multi-year deal with OpenAI could unlock $135 billion in revenue and mount a serious challenge to Nvidia Corp.’s (NASDAQ:NVDA) long-standing dominance, according to Goldman Sachs.

Benzinga

EXCLUSIVE: Envoy Medical Cuts Capital Needs After FDA Approval For Final Trial Stage Of Cochlear Implant Trial

Envoy Medical Inc. (NASDAQ:COCH) announced on Tuesday that it has received U.S. Food and Drug Administration (FDA) approval to expand its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data from the first 10 patients.

Benzinga

$68 million COVID-era federal funding loss and other potential cuts threaten Texas opioid fight

In addition to the cuts, local nonprofits are also having problems accessing federal help for opioid reversal medication, such as Narcan.

The Texas Tribune

Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket

Shares of Telomir Pharmaceuticals Inc (NASDAQ:TELO) rose sharply in pre-market trading after the company released promising preclinical study results for its lead compound, Telomir-1.

Benzinga

Famed Short-Seller Jim Chanos Questions AMD's Revenue Forecast Following OpenAI Deal: 'Shouldn't This Deal Bring In More… For $AMD?'

Renowned short-seller Jim Chanos has publicly questioned the financial benefits of the landmark partnership between Advanced Micro Devices Inc. (NASDAQ:AMD) and OpenAI, suggesting the deal may not be as lucrative for AMD as it appears.

Benzinga

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

Benzinga

AngioDynamics Eyes Growth Despite Tariffs

AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Teladoc (TDOC) Shares Climb On Bullish Commentary From Citron Research

Shares of Teladoc Health Inc (NYSE:TDOC) are surging Friday morning after Citron Research posted bullish comments on the telehealth provider, asserting they were “not wrong, just early” on the stock’s potential. The commentary sparked renewed investor interest, pushing the stock higher in early trading.

The Guardian - US

Anti-abortion groups furious as FDA approves generic abortion pill

Abortion rights supporters hail win for evidence-backed medicine as Evita Solutions’ generic version of mifepristone given approval

Kiplinger

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap

Health care stocks are on track for their best week in years, yet even after the rally, several pharma giants remain absurdly cheap by market standards.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket

Shares of Concorde International Group Ltd. (NASDAQ:CIGL) rose sharply in pre-market trading as the company revealed that its Board of Directors and Compensation Committee had approved a 2025 Equity Incentive Plan earlier that day.

Benzinga

Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years

Investors cheered a breakthrough drug pricing agreement between President Donald Trump and Pfizer Inc. (NYSE:PFE), sparking a sector-wide surge in health care stocks that delivered the biggest rally in five years.

Axios

Inside the TrumpRx website and its unusual launch

Trump has been urging prescription drug manufacturers to lower U.S. prices.

Benzinga

Moderna Stock Is Rallying Wednesday: What's Driving The Action?

Moderna Inc (NASDAQ:MRNA) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc (NYSE:PFE) and the Trump administration to lower prescription drug prices.

Benzinga

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

The Guardian - UK

Big pharma is at war with the UK, and the government can’t back down now

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain, says director of Global Justice Now Nick Dearden

Evening Standard

Baroness Michelle Mone-linked company loses £122m High Court battle with government over faulty PPE

Michelle Mone’s husband Douglas Barrowman branded the PPE Medpro defeat in the High Court a “whitewash”

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.